Effects on Pain

  • Acute vs. Chronic Pain

    • Acute Pain: This is the immediate sensation of pain resulting from a specific injury. For example, if someone falls and hits their head, they will instantly feel pain in that area. Acute pain is usually temporary and goes away as the injury heals, acting as a signal to protect the body from further harm.

    • Chronic Pain: This occurs if an injury causes irreparable damage. Chronic pain is a persistent state of suffering that can last for months or even years. It can arise from conditions like arthritis or nerve damage. Unlike acute pain, chronic pain can lead to emotional impacts, such as depression or anxiety, because individuals may feel helpless or frustrated when the pain doesn't go away.

    • Global Prevalence: Approximately 20\,\text{\textperthousand} of the world's population is currently suffering from some form of chronic pain, highlighting the significant health issue it represents globally.

  • Major Types of Chronic Pain

    • Nociceptive Chronic Pain: This type of pain is caused by direct damage to body tissues, like when you sprain your ankle. It involves tissues such as muscle, bone, and joints, but it excludes pain arising from issues in the nervous system. An example would be a permanent neck injury resulting from a fall that leads to ongoing discomfort.

    • Neuropathic Chronic Pain (Neuropathy): This is caused by direct damage to the nervous system itself, which makes it more complex and often harder to treat. Common causes of neuropathic pain include:

      • Diabetic Neuropathy: This occurs when high blood sugar damages the nerves over time, leading to pain in the feet and hands, often described as burning, stabbing, or tingling sensations.

      • Chemotherapy-Induced Neuropathy: Damage to nerves and neurons can happen during and after cancer treatment, resulting in pain and sensory changes.

      • Immune/Genetic Diseases: Conditions like Multiple Sclerosis involve the immune system attacking the nervous system, which can lead to chronic pain.

  • Current Treatment Limitations

    • Opiates: Currently the most common treatment for chronic pain, examples being morphine or oxycodone. While they can be effective, they come with significant risks of addiction and abuse, making them a controversial choice for long-term pain management.

    • Patient Dissatisfaction: Approximately 40\,\text{\textperthousand} of chronic pain patients report being unsatisfied with their current treatment regimen, suggesting that many feel their pain is not adequately managed.

    • Medical Cannabis: Increasingly, medical cannabis is being explored and used, as it has shown promise in alleviating pain for various conditions. It is becoming one of the most frequent uses of cannabis in medical settings, as patients seek alternatives to traditional pain medications.

  • Animal Research Models for Pain

    • Measuring Pain in Animals: Studying pain in animals is challenging because researchers cannot verbally ask them how they feel. Therefore, scientists must observe the animals' behaviors and reactions to infer the timing and intensity of the pain they are experiencing.

  • Acute Pain Models

    • Tail Flick Experiment: In this study, a mouse is placed on a platform where an infrared heat source is directed at its tail. The quickness with which the mouse flicks its tail away from the heat is measured to assess its pain response.

    • Hot Plate Experiment: A mouse is put in a clear cylinder on a heated plate. The temperature is gradually increased until the mouse shows a negative response, such as picking up a leg or jumping. These experiments aim to pinpoint the temperature at which the animal feels pain without causing permanent harm.

  • Chronic Pain Models

    • Plantar Test (Inflammatory Pain): In this experiment, researchers inject an irritant into the bottom of a mouse's foot. The chemical itself might not initially cause pain, but it leads to inflammation, mimicking chronic pain conditions like osteoarthritis.

    • Chemotherapy-Induced Neuropathy: To better understand how pain develops in humans, researchers administer chemotherapy drugs to mice, causing nerve damage similar to what cancer patients may experience.

  • THC (Tetrahydrocannabinol) as an Analgesic

    • Efficacy in Animals: THC, a major compound in cannabis, is very effective at eliminating both acute and chronic pain in animal models. When studying new pain-relief drugs, one must demonstrate hyperalgesia, defined as a substantial ability to reduce pain response.

  • Administration Routes

    • Systemic: THC is often administered orally in pill form or inhaled, commonly seen in cannabis-based treatments.

    • Local: This involves injecting pure THC directly at the pain site; however, it is less common in clinical practice due to practical considerations.

  • Managing Psychoactive Side Effects

    • The psychoactive effects of THC, which can lead to feelings of being high, are mediated by CB1 receptors in the brain. Researchers are exploring ways to achieve pain relief without these unwanted side effects by focusing on:

      • CB2 Receptor Specificity: Evidence suggests that CB2 receptors may play a more significant role in alleviating pain. Developing drugs that specifically target CB2 receptors could reduce the psychoactive effects associated with THC.

      • Ajulemic Acid: This is a synthetic version of a THC metabolite that can relieve pain but cannot cross the blood-brain barrier (BBB\text{BBB}), thus preventing any psychoactive side effects.

      • THC and Opioid Synergy: There is an interaction between the endocannabinoid and opioid systems, which can be beneficial. Using THC together with opioids may allow for lower, less toxic doses of THC to achieve sufficient pain relief while reducing reliance on stronger opioids.

  • CBD (Cannabidiol) and Chronic Pain Mechanisms

    • Efficacy Profile: CBD is typically ineffective for acute pain (like a headache) and is usually handled by over-the-counter medications such as Tylenol or NSAIDs (Non-Steroidal Anti-Inflammatory Drugs). Long-term use of these medications can lead to serious side effects, especially liver damage, which is why alternatives are being researched. CBD, however, is highly effective for both inflammatory and neuropathic chronic pain.

  • Specific Mechanisms

    • TRPV1 Receptor: CBD appears to act through the TRPV1 receptor found on neurons. When activated, it may help in managing pain signaling.

    • TNF Alpha (TNF-β\text{TNF-}\beta): CBD may block the secretion of a substance called Tumor Necrosis Factor Alpha. This molecule is a major cause of inflammation and is often found at elevated levels in conditions like arthritis.

    • Synergy with THC: Interestingly, while CBD usually reduces THC's effects in other contexts, here it appears to enhance THC's pain-relieving properties. This allows for the possibility of using lower doses of THC without losing effectiveness.

  • Manipulating the Endocannabinoid System

    • Advantages over Exogenous Cannabinoids: Modifying the body's natural endocannabinoid system can lead to pain relief without the issues of legality and side effects related to using cannabis directly.

  • Targeting Signaling and Metabolism

    • Allosteric Modulators: Researchers are developing agents that increase natural signaling at the CB1 receptor to block inflammatory and neuropathic pain without introducing external cannabinoids.

    • Metabolic Inhibitors: By inhibiting enzymes like FAAH (Fatty Acid Amide Hydrolase) and MAGL (Monoacylglycerol Lipase), levels of the body's own cannabinoids can rise. For example, mice that lack FAAH seem to be less sensitive to pain.

      • Inhibitor Limitations: The effectiveness of these treatments can be limited by how much the body naturally produces cannabinoids and what its feedback mechanisms are.

      • Tolerance Issues: When using MAGL inhibitors, tolerance can develop over time, but this does not seem to occur with FAAH inhibitors, making them a more sustainable option.

      • Combined Strategy: Combining complete FAAH inhibition with partial MAGL inhibition may provide effective pain relief while preventing tolerance issues related to using only MAGL inhibitors.

  • The Role of CB2 Receptors in Chronic Pain

    • Expression and Location: CB2 receptors are found mainly in immune cells and glial cells (support cells in the nervous system). Though they can be present in the brain, they are not found in high numbers in neurons unless there is inflammation. Because of their specific role in chronic pain, they are a promising target for creating new pain relief therapies.

  • Experimental Drug: AM1710

    • AM1710 is a drug currently being tested that acts as a CB2 agonist.

    • It has demonstrated abilities to lessen neuropathic pain and lower levels of TNF-β\text{TNF-}\beta, which are linked to inflammation.

    • Notably, with AM1710, no tolerance has been observed, suggesting it could possibly be used for long-term chronic pain management without diminishing effectiveness over time.

  • Clinical Outcomes and Case Studies

    • General Clinical Findings: About 50\,\text{\textperthousand} of patients with chronic pain report having received no relief from conventional treatments.

    • Out of 2929 clinical trials exploring cannabinoids for chronic pain, 2222 found significant improvement in pain management, showing a trend towards effective use.

    • HIV Neuropathy: Cannabinoids have shown effectiveness in treating neuropathy related to HIV, where few other viable treatments exist, making them an important option for these patients.

    • Side Effects: Reports from trials indicate that the side effects of using cannabis were mostly mild to moderate (such as headache, dizziness, nausea, and drowsiness) with fewer reports of severe side effects, showcasing a relatively safe profile.

  • The COMPASS Study

    • This was the largest study conducted to assess cannabis for pain, involving 431431 patients.

    • Structure: The study divided participants into two groups: those who were previous or current cannabis users (who used it in forms like smoking or edibles) and a control group of non-users.

    • Results: The analysis revealed that the cannabis users experienced significant decreases in pain. Although they did have a higher instance of non-severe adverse events (like dizziness and nausea), there was no notable increase in severe events, indicating overall safety.

  • The Pfizer FAAH Inhibitor Trial (2012)

    • Pfizer developed a FAAH inhibitor and tested it on patients with osteoarthritis.

    • The drug successfully reduced FAAH activity by 96\,\text{\textperthousand}, indicating strong effectiveness in lowering specific pain mediators.

    • Failure and Reason: Despite these promising numbers, the trial did not lead to a reduction in pain levels for patients. The study attributed this failure to testing the drug in cases of spontaneous pain (which is caused by the body's internal reactions rather than an external stimulus). Previous animal studies had shown the drug was only effective for induced pain (like pain caused by a heat source).

    • Subsequent animal tests confirmed this limitation, leading Pfizer to decide against further trials using it for induced pain.